







特 別 講 演 会 要 旨
2008年 11月から2009 年 5月までの間に東北医学会主催で行われた特別講演会は
次のとおりです．
1. 2008年 11月 14日（金）脳神経外科担当
Gregory T.Clement PhD, FInstP :Department
 
of Radiology, Harvard Medical School/Focused
 
UItrasound Program,Brigham and Women’s Hos-
pital
“Therapeutic Uses of High Intensity Focused
 
Ultrasound”
要旨 :The idea of replacing a surgeon’s scalpel with
 
a noninvasive procedure has attracted attention in
 
medicine for more than half a century. In fact, it
 
predates ultrasound’s suggested use as a diagnostic tool.
However,early treatments starting in the 1950s retur-
ned variable results due to the inability to monitor and
 
control treatments. It is indeed primarily new develop-
ments in targeting and monitoring over the past decade
 
that have made many previously suggested procedures
 
now reliable and practical. Near  real time
 
noninvasive monitoring has permitted quality assurance
 
and improved treatment targeting, monitoring, and
 
evaluation. Concurrently, signiﬁcant  advancements
 
have occurred in high power ultrasound transducer
 
array designs, materials, and driving systems. The
 
combined imaging and driving technologies have all-
owed greatly increased beam control, resulting in
 
reduced treatment times and the ability to correct
 
distorted beams. By mid 2007 the estimated number of
 
high intensity focused ultrasound, or (HIFU)clinical
 
treatments had reached 100,000 worldwide［1］.
Ultrasound now has the potential become a leading
 
method for realizing noninvasive surgical procedures,
due to its ability to accurately focus energy deep into
 
the body in order to heat and destroy precise volumes of
 
tissue. A wide range of treatments have been inves-
tigated to treat tumors,to ablate the prostate for benign
 
hyperplasia (BHP), to control bleeding, for cardiac
 
treatments,to treat various eye conditions,and to treat
 
brain disorders［2］. An increasing number of clinical
 
treatments and trials are being conducted worldwide
 
for tissue ablation in various organs, while exciting
 
prospects for enhancing and expanding present ther-
apies are underway.
As technological advancements improve the ability to
 
control energy deposition, there is an increasing con-
certed eﬀort toward understanding the biological inter-
actions and consequences of focused ultrasound. Abla-
tion of tissue by coagulative necrosis―achieved by
 
raising its temperature above approximately 60 C―is
 
the most understood mechanism of cell death. How-
ever,numeric and experimental studies are examining
 
improved and faster treatments by promoting advanced
 
treatment planning and cavitation enhanced cell dam-
age. Methods are being investigated that induce
 
cavitation with short,high amplitude pulses,as well as
 
with the introduction of microbubbles into the blood-
stream. Beyond thermal ablation,biological responses
 
to ultrasound oﬀer the exciting prospect of greatly
 
expanding the use of focused ultrasound to include
 
targeted drug delivery and certain therapies. Exam-
ples of such responses include increased gene transfec-
tion rates, the induction of cell apoptosis, and the
 
opening of the blood brain barrier (BBB).
Factors that continue to limit focused ultrasound are
 
distortion of the ultrasound by scattering and refraction
 
due to heterogeneous tissues,and prolonged treatment
 
times resulting from the relatively small size of the
 
ultrasound focus. Presently, new treatment planning
 
methods are being implemented that perform ultra-
sound phase aberration correction using diagnostic
 
pre imaging combined with mathematical modeling of
 
the ultrasound and its associated thermal ﬁelds. These
 
methods use input from pre planning images supplied
 
by CT or MRI in order to restore a distorted ultrasound
 
focus in the body. It is expected that the wavevector
 
domain kernel,when similarly applied in the clinic,will
 
result in improved and expanded treatment volumes.
Similarly pre planning and array techniques allow
 
treatments as large as a few cc in a single sonication
 
lasting under 30 s.
Arguably,the most exciting―and also most challeng-
ing―HIFU applications involve noninvasive brain ther-
apy［3］. In fact,it was long believed that the attenua-
tion and distortion caused by the skull was so severe
 
that it created an impenetrable barrier,making transs-
kull therapies impossible. Contemporary work, how-
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ever,has shown that focusing through the intact skull is
 
possible［4］. Furthermore, technological  advance-
ments have made it practical,owing to the development
 
of high powered transducer arrays and high perfor-
mance computers to calculate the corrections necessary
 
to restore a focus in the brain. Similarly,the ability to
 
target and monitor the deposition of ultrasound energy
 
in the brain has improved dramatically over the past
 
half century. Radiological developments including X
 
ray computed tomography(CT)followed by magnetic
 
resonance imaging (MRI) made millimeter precision
 
registration with brain structures possible. This pro-
gression of improvements has led to the present state of
 
research,where non invasive transskull focusing for the
 
purposes of thermal ablation has reached the early
 
stages of clinical testing in our hospital.
［1］“Therapeutic Ultrasound Report”;http://www.
med device.com/Therapeutic Ultrasound Repo.
html.
［2］G.T.Clement, “Perspectives in clinical uses of
 
high intensity focused ultrasound,”Ultrasonics,
vol.42,Aug.2004,pp.1087 93.
［3］K.Hynynen and G.Clement, “Clinical applica-
tions of focused ultrasound the brain,”Interna-
tional Journal of Hyperthermia,vol.23,Mar.2007,
pp.193 202.
［4］G.T.Clement and K.Hynynen, “A non invasive
 
method for focusing ultrasound through the
 
human skull,”Physics in Medicine and Biology,
vol.47,Apr.2002,pp.1219 36.
（文責 :中川敦寛）
2. 2008年 11月 17日（月）ゲノム生物学分野担当
Prof. Gayle E.Woloschak :Northwestern Uni-
versity
“Applications of radiation induced nanoparticles
 







3. 2008年 11月 25日（火）医化学分野担当
Dr.Vincent P.Kelly:Trinity College Dublin
“Food for thought ; the micronutrient queuine
 






































4. 2008年 12月 1日（月）整形外科学分野担当
Prof.Olivier Gagey:Institut d’Anatomie,Univer-
site?Paris Sud
“Thinking the muscle function in a diﬀerent
 
































5. 2008年 12月 1日 臨床薬学分野担当
Robert H.Fagard,MD,PhD :Hypertension and
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7. 2008年 12月 9 日（火）整形外科学分野担当
1)Prof. Tae Soo Park :Department of Orth-
opaedic Surgery,Hanyang University Guri Hospi-
tal













2）Prof. Kwan Won Lee:Department of Orth-
opaedic Surgery,Eulji University Hospital
“Repair of Massive Rotator Cuﬀ Tear with
 















8. 2008年 12月 12日（金）CJD早期診断・治療法開発分
野担当
Dr. Susie ElSaadany:Faculty of Medicine,Uni-
versity of Ottawa
“Preliminary Quantitative Risk Assessment of
 
Developing Variant Creutzfeldt Jakob Disease
(vCJD)from Human Islet Cell Transplantation”





























9. 2009 年 1月 6日（火）先端再生生命科学寄附講座担当
William A.Petri,Jr.教授 :University of Virginia
 
Health Sciences Center
“Genetic polymorphisms in the leptin signaling
 
pathway inﬂuencing susceptibility to amebic
 





















る予定である． （文責 :菅原 明）
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10. 2009 年 2月 3日（火）国際保健学分野担当
Mr.Kaj Essinger :Swedish Medical Injury Insur-
ance
“スウェーデンの医療事故対策と医療傷害保険”
11. 2009 年 2月 12日（木）腎・高血圧・内分泌学分野担
当
Prof. Ju?rgen Floege, M.D.:Division of Ne-









































12. 2008年 2月 16日（月）腎・高血圧・内分泌科担当
Prof. Curt D.Sigmund, Ph.D.:Roy J.Carver
 
Chair in Hypertension Research, Departments of
 
Internal Medicine and Molecular Physiology and
 
Biophysics,Roy J.and Lucille A. Carver College
 
of Medicine,University of Iowa
“Endothelial  and smooth muscle PPAR γ
(gamma) are critical regulators of vascular
 
function”


























13. 2009 年 3月 4日（水）脳神経外科担当
Weimin Wang MD :Department of Neurosurgery
 
Guangzhou Liuhuaqiao Hospital


































14. 2009 年 3月 7日（土）腎・高血圧・内分泌学分野担当
William G Couser, MD :Aﬃliate Professor of
 
Medicine University of Washington Seattle,WA
 
USA
“WHY IS CHRONIC KIDNEY DISEASE SO
 
IMPORTANT?”
要旨 :Immediate Past President, International Soci-




Although nephrology has traditionally been a disci-
pline focused on renal replacement therapy, the past
 
decade has witnessed a marked increase in attention to
 
what is now termed chronic kidney disease, or CKD.
The deﬁnition of CKD rests largely on criteria including
 
measurements of GFR and albuminuria,and the preva-
lence of CKD has ranged from 10 13% of the general
 
population in most countries. The risk of CKD is
 
highest in patients with hypertension, diabetes and
 
cardiovascular disease,Not only are these entities ones
 
that increase risk for CKD,but CKD alone is an impor-
tant risk factor for hypertension and cardiovascular
 
disease. Indeed,patients with only a minor decrease in
 
GFR and/or increase in urinary albumin excretion are
 
at up to 8 fold greater risk of cardiovascular disease,
which kills more patients than ever progress to require
 
renal replacement. Despite these facts, awareness of
 
CKD remains very low among both physicians and
 
patients.
These observations have created many opportunities
 
for fruitful interactions among nephrologists, car-
diologists, hypertension specialists, and endo-
crinologists,including the societies that represent them.
Important to the eﬀectiveness of these interactions are
 
common levels of appreciation for the beneﬁts and
 
limitations of CKD detection programs,management of
 
risk factors including hypertension and follow up pro-
grams focused on monitoring renal abnormalities.
Increasing global awareness of CKD is a major focus of
 
World Kidney Day celebrated March 23,2009. Several
 
programs including ISN COMGAN research programs
 
are providing tools for early detection and prevention
 
programs in the developing world. It is now time for
 
the development of a coalition of nephrologists,hyper-
tension specialists,cardiologists and endocrinologists to
 
come together and join forces in creating common
 
guidelines and screening programs for combating kid-
ney and cardiovascular disease and spearheading eﬀorts
 
at the government level to get CKD included in global
 
public health agendas for the 21?century.
（文責 :小川 晋）
15. 2009 年 3月 19 日（金）機能薬理学分野担当
Prof. Colon. L. Masters: Mental  Health
 
Research Institute,The University of Melbourne
“Aβoligomers as the diagnostic and therapeutic
 













Compelling evidence shows that the Aβamyloid
 
peptide is the central  biochemical  marker of
 
Alzheimer’s disease,and is the most likely cause of the
 
neurodegeneration manifest in synaptic dysfunction and
 
eventual neuronal loss. Pathways up stream of Aβ
production provide therapeutic targets amenable to
 
protease inhibition/modulation. Strategies which
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aﬀect APP traﬃcking may also prove of value. Down-
stream,pathways promoting the degradation of Aβor
 
modulating clearance from the brain also oﬀer windows
 
for therapeutic opportunity.
Central interest lies in the mechanism through which
 
Aβundergoes toxic gain of function, inducing neur-
onal damage. This provides the most direct route for
 
therapeutic intervention,with least risk of therapeutic
 
side eﬀects,since Aβtoxicity is unlikely to mimic any
 
normal function. Two principal hypotheses have emer-
ged to explain Aβtoxicity:redox chemistry associat-
ed with the Cu/Zn metal binding sites on Aβ,and lipid
 
interactions associated with the α/βconformation of
 
the hydrophobic C terminus. Drugs targeting these
 
mechanisms are now in clinical development with
 
encouraging preliminary results.
Either as a soluble oligomer or insoluble amyloid
 
ﬁbril,the accumulation of the Aβfragment provides a
 
pivotal biomarker,currently being developed as a neur-
oimaging target and a blood/CSF biomarker for
 
eﬃcacy of therapeutic intervention.
（文責 :谷内一彦)
16. 2009 年 4月 2日（木）機能薬理学分野担当
Prof. Birendra N.Mallick :School of Life Sci-
ences,Jawaharlal Nehru University






























17. 2009 年 4月 9 日（木）医化学分野担当
Dr. Jingbo Pi:The Hamner Institue Research
 
Triangle Park,North Carolina
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18. 2009 年 4月 27日（月）病理診断学分野担当
Prof. Jian Jun YU :Department of Oncological
 
Surgery,The Aﬃlicated Cancer Hospital,Ningxia
 
Medical University
“ER,PR and HER 2 Expression on Breast Car-
cinoma of Han and Hui National Patients in
 
Ningxia”
要旨 :Objective:The Breast cancer is one of the
 
commonest malignant tumor in the female in Ningxia.
The incidence of breast cancer is presented in an
 
increasing tendency recent year. The expressions of
 
the sex hormone receptors and oncogenes are related
 
closely with the biology characters of breast cancer.
In our experiment,the expression of estrogen receptor
(ER), progesterone receptor (PR) and epidermal
 
growth factor receptor 2(Her 2) in breast cancer tis-
sue of 842 cases were studied and the expression of ER,
PR and Her 2 was compared between Han and Hui
 
nationality.
Materials and methods:Collect the clinical data of
 
842 breast cancer cases,which includes Han and Hui
 
nationalities,who has the operation in our hospital and
 
ﬁnal diagnosis is primary breast cancer by pathological
 
result since 2002 to 2008. The diﬀerence of ER,PR and
 
HER 2 expression were compared between Han and
 
Hui nationality.
Result:1,ER expression rate is 65.72%,PR expres-
sion rate is 73.70%, Her 2 expression rate is 89.18%
(IHC). ER expression rate is 65.80%, PR expression
 
rate is 74.22%,Her 2 expression rate is 89.51%(IHC)in
 
772 cases and Her 2 expression rate is 34.78% (CISH)
in 70 cases of Han nationality. ER expression rate is
 
62.86%,PR expression rate is 67.57%,Her 2 expression
 
rate is 90.00%(IHC) in 70 cases of Hui nationality.
The expression of ER, PR and HER 2 have not
 
signiﬁcal diﬀerence between Han and Hui nationality
(P＞0.05).
Conclusion:ER expression rate is 65.72%,PR expres-
sion rate is 73.70%, Her 2 expression rate is 89.18%
(IHC) in all patients and Her 2 expression rate is
 
34.78% (CISH)in Han nationality. The expression of
 
ER, PR and HER 2 have not signiﬁcal diﬀerence
 
between Han and Hui nationalities.
（文責 :笹野公伸）
19. 2009 年 5月 11日（月）消化器内科担当
1)Prof. David C.Whitcomb:Departments of
 
Medicine, Cell biology and Physiology, and
 
Human Genetics,University of Pittsburgh



































2)Prof. Craig D.Logsdon :Department of Can-
cer Biology,The University of Texas,M.D.Ander-
son Cancer Center


















































20. 2009 年 4月 28日（火）血液・免疫学分野
Prof. B.D.Stollar:Tutts University, New Eng-
land medical


































21. 2009 年 4月 30日（木）運動学分野担当
Prof.Myra Nimmo:英国ラフラバラ大学スポーツ
運動科学部運動生理学教室，同運動科学部長




























IL 6だけではなく，IL 6の可溶性受容体である IL 6R α





22. 2009 年 5月 20日（水）脳神経外科担当
Prof.Mohamed Safwat Ibrahim:Mansoura Uni-
versity Faculty of Medicine,Neurosurgery Depart-
ment

























23. 2009 年 5月 28日（木）中心血圧研究講座担当
Professor Michael F.O’Rourke:St. Vincent’s
 
Clinic/University of New South Wales, Sydney,
Australia
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